Proteomics: A Promising Approach for Cancer Research
Proteome Signaling Dysregulation in Cancer, Therapeutic Interventions, and Future Perspectives, Volume 2
- 1st Edition - January 1, 2026
- Imprint: Academic Press
- Editors: Muneeb U Rehman, Sabhiya Majid, Shafat Ali
- Language: English
- Paperback ISBN:9 7 8 - 0 - 4 4 3 - 2 3 9 0 8 - 3
- eBook ISBN:9 7 8 - 0 - 4 4 3 - 2 3 9 0 7 - 6
Proteomics: A Promising Approach for Cancer Research Volume 2 Proteome signaling dysregulation in cancer, therapeutic interventions, and future perspectives provides an updated o… Read more
Purchase options
Proteomics: A Promising Approach for Cancer Research Volume 2 Proteome signaling dysregulation in cancer, therapeutic interventions, and future perspectives provides an updated overview of scientific knowledge, achievements, and findings in the field of cancer proteomics. The field of cancer proteomics is very dynamic, with emerging trends specifically related to clinical solutions. The book content was developed to help readers get up to speed on the topic and easily apply learnings into research or clinical practice.
Volume 2 covers proteome signaling, their dysregulation to therapeutics options and future prospects in 17 different signaling pathways. It capitalizes the enormous interest in proteomics among academics and gives new viewpoints on this topic in cancer treatment. It is a valuable resource for cancer researchers, oncologists, graduate students, and members of biomedical field who are interested in the potential of proteomics in cancer research and treatment.
- Provides up to date information on current cancer proteomics research developed globally
- Presents from basic research aspects to clinical implications of proteomics on cancer diagnosis and potential treatments
- Discusses challenges and future developments of the field to leverage further research and applicability in clinical setting
- Contains exclusive information about research on proteome signaling dysregulation in cancer and therapies globally
- Includes recent details which will be the prerequisite requirement for any researcher who wants to work on cancer proteomics, proteome signaling dysregulation and therapeutics
Researchers and graduate students on cancer research and bioinformatics, oncologists
Clinical researchers
Clinical researchers
1. Breast cancer: JAK/STAT signaling dysregulation, potential proteomic techniques, therapeutic strategies, and future perspectives
2. Colorectal cancer: Notch signaling dysregulation, potential proteomic techniques, therapeutic strategies, and future perspectives
3. Lung cancer: Akt/PKB signaling dysregulation, potential proteomic techniques, therapeutic strategies, and future perspectives
4. Leukemia: Hedgehog signaling dysregulation, potential proteomic techniques, therapeutic strategies, and future perspectives
5. Gastric cancer: AMPK signaling dysregulation, potential proteomic techniques, therapeutic strategies, and future perspectives
6. Pancreatic cancer: Wnt signaling dysregulation, potential proteomic techniques, therapeutic strategies, and future perspectives
7. Cervical cancer: TGFβ signaling dysregulation, potential proteomic techniques, therapeutic strategies, and future perspectives
8. Ovarian cancer: VEGF signaling dysregulation, potential proteomic techniques, therapeutic strategies, and future perspectives
9. Brain cancer: Hippo signaling dysregulation, potential proteomic techniques, therapeutic strategies, and future perspectives
10. Endometrial cancer: cAMP-dependent signaling dysregulation, potential proteomic techniques, therapeutic strategies, and future perspectives
11. Lymphoma: TLR signaling dysregulation, potential proteomic techniques, therapeutic strategies, and future perspectives
12. Thyroid cancer: MAPK/Erk signaling dysregulation, potential proteomic techniques, therapeutic strategies, and future perspectives
13. Kidney cancer: mTOR signaling dysregulation, potential proteomic techniques, therapeutic strategies, and future perspectives
14. Liver cancer: Insulin signal transduction pathway dysregulation, potential proteomic techniques, therapeutic strategies, and future perspectives
15. Bladder cancer: PI3K/Akt/mTOR signaling dysregulation, potential proteomic techniques, therapeutic strategies, and future perspectives
16. Skin cancer: Eph/ephrin signaling dysregulation, potential proteomic techniques, therapeutic strategies, and future perspectives
17. Esophageal Cancer: Nodal signaling dysregulation, potential proteomic techniques, therapeutic strategies, and future perspectives
2. Colorectal cancer: Notch signaling dysregulation, potential proteomic techniques, therapeutic strategies, and future perspectives
3. Lung cancer: Akt/PKB signaling dysregulation, potential proteomic techniques, therapeutic strategies, and future perspectives
4. Leukemia: Hedgehog signaling dysregulation, potential proteomic techniques, therapeutic strategies, and future perspectives
5. Gastric cancer: AMPK signaling dysregulation, potential proteomic techniques, therapeutic strategies, and future perspectives
6. Pancreatic cancer: Wnt signaling dysregulation, potential proteomic techniques, therapeutic strategies, and future perspectives
7. Cervical cancer: TGFβ signaling dysregulation, potential proteomic techniques, therapeutic strategies, and future perspectives
8. Ovarian cancer: VEGF signaling dysregulation, potential proteomic techniques, therapeutic strategies, and future perspectives
9. Brain cancer: Hippo signaling dysregulation, potential proteomic techniques, therapeutic strategies, and future perspectives
10. Endometrial cancer: cAMP-dependent signaling dysregulation, potential proteomic techniques, therapeutic strategies, and future perspectives
11. Lymphoma: TLR signaling dysregulation, potential proteomic techniques, therapeutic strategies, and future perspectives
12. Thyroid cancer: MAPK/Erk signaling dysregulation, potential proteomic techniques, therapeutic strategies, and future perspectives
13. Kidney cancer: mTOR signaling dysregulation, potential proteomic techniques, therapeutic strategies, and future perspectives
14. Liver cancer: Insulin signal transduction pathway dysregulation, potential proteomic techniques, therapeutic strategies, and future perspectives
15. Bladder cancer: PI3K/Akt/mTOR signaling dysregulation, potential proteomic techniques, therapeutic strategies, and future perspectives
16. Skin cancer: Eph/ephrin signaling dysregulation, potential proteomic techniques, therapeutic strategies, and future perspectives
17. Esophageal Cancer: Nodal signaling dysregulation, potential proteomic techniques, therapeutic strategies, and future perspectives
- Edition: 1
- Published: January 1, 2026
- Imprint: Academic Press
- Language: English
MU
Muneeb U Rehman
Muneeb U Rehman (Ph.D.) is a Faculty member at College of Pharmacy, King Saud University, Riyadh, Saudi Arabia. He holds a doctorate in Toxicology (specialization in cancer biology and natural product research) from Jamia Hamdard, New Delhi, India. Dr. Rehman has more than 10 years of research and teaching experience in the field of toxicology, cancer biology, natural product pharmacology and pharmacogenomics. He is the recipient of several national and international fellowships and awards. He has published more than 100 research papers in peer-reviewed, international journals, and has 5 edited books and 30 book chapters. Dr. Rehman is on the editorial boards and is a reviewer of several high-impact, international scientific journals. He is also a life member of various international societies and organizations. Currently, Dr. Rehman is engaged in studying the molecular mechanisms of cancer prevention by natural products and the role of pharmacogenomics and toxicogenomics in evaluating the effectiveness and safety of drugs.
Affiliations and expertise
College of Pharmacy, King Saud University, Riyadh, Saudi ArabiaSM
Sabhiya Majid
Sabhiya Majid, Ph.D. is a Professor and Chairperson of the Department of Biochemistry, Govt. Medical College Srinagar (GMC Sgr.), J&K, India. Prof. Majid has 30 years of experience in teaching, research and diagnostic biochemistry, having published around 100 research papers in journals of repute, many books and 12 book chapters. She has been the recipient of several fellowships, awards and grants from various reputed funding agencies. She has been the nodal officer and implemented various research and infrastructure development schemes including Fund for Improvement of Science & Technology Infrastructure, Department of Science & Technology, Govt. of India. She is a member of several scientific associations and boards of undergraduate, postgraduate and research studies. She is on the reviewer panel of a number of online peer-reviewed journals. Having moved on from her doctoral work on nutritional modulation of carcinogenesis to understanding the molecular basis of various disease processes, her current research focuses on non invasive cancer markers.
Affiliations and expertise
Professor and Chairperson, Department of Biochemistry, Government Medical College, Srinagar, IndiaSA
Shafat Ali
Shafat Ali (Ph.D.) pursued his BSc. from University of Kashmir and Masters in Zoology from Barkatullah Vishwavidyalaya, India. Currently he is engaged in research work for last 5 years at Cytogenetics and Molecular Biology Laboratory, Centre of Research for Development, University of Kashmir, Department of Biochemistry, Government Medical College, Srinagar, Jammu and Kashmir, and ICMR funded Multidisciplinary Research Unit, Government Medical College, Srinagar, Jammu and Kashmir, India, with specialization in the field of reproductive immunogenetics, cytokine biology, gynaecology and obstetrics, molecular biology, cancer biology and cytogenetics. He has 5 years of research experience and 5 years of teaching experience. He has more than 20 book chapters, several edited books and numerous peer-reviewed, international research publications to his credit. Mr. Ali is also the reviewer of many reputed international journals. Presently, Mr. Ali is involved in studying immunogenetic mechanisms involved in recurrent pregnancy loss
Affiliations and expertise
Cytogenetics and Molecular Biology Laboratory, Centre of Research for Development, University of Kashmir, Jammu and Kashmir, India